New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Ra Pharmaceuticals Announces $58.5M Series B Financing
-
Apprenda Raises $24M from Safeguard Scientifics, New Enterprise Associates and Ignition Partners
-
Ziarco Appoints Mike Grey as Executive Chairman of Board of Directors
-
Global Genes Announces Fourth Annual RARE Tribute to Champions of Hope Award Recipients
-
Form SC 13D/A Vitae Pharmaceuticals, Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
CIT GAP Funds Invests in PockitShip
-
Allergan to Acquire Oculeve Dry Eye Disease Development Programs
-
Form 4 Vitae Pharmaceuticals, For: Jul 01 Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Cortendo AB: Cortendo Provides 2015 Half-Year Update on Corporate Progress
-
CIT GAP Funds Invests in TypeZero Technologies
-
ESSA Pharma Inc. Announces Appointment of New Director
-
HackerOne Raises $25 Million to Make the Internet Safer
-
Cloud-Based Tax Platform Canopy Raises $8 Million in Series A Funding
-
Clementia Pharmaceuticals Raises U.S. $60 Million in Mezzanine Financing to Support Development of Palovarotene for Fibrodysplasia Ossificans Progressiva
-
Sleep Startup Casper Raises $55 Million in Series B Funding
-
Enigma Raises $28.2 Million in Series B Funding to Extend Enterprise Operations and Add Talent
-
Online Custom Framing Startup Framebridge Raises $7.7 Million in Series A Funding
-
Supernus Corrects Earlier Statement Regarding Distribution of Common Stock by NEA
-
Supernus Corrects Earlier Statement Regarding Distribution of Common Stock by NEA
-
Form SC 13D/A SUPERNUS PHARMACEUTICALS Filed by: NEW ENTERPRISE ASSOCIATES 11 LP
-
Study of 106,000 Software Development Organizations Reveals That The Way the World Creates Software is Broken
-
ARCA biopharma Announces Closing of $37 Million Private Placement
-
Form 4 SUPERNUS PHARMACEUTICALS For: Jun 15 Filed by: NEW ENTERPRISE ASSOCIATES 11 LP
-
Cleave Biosciences to Present at JMP Securities Life Sciences Conference 2015
-
Supernus Pharmaceuticals (SUPN) Announces 3.9M Common Stock Distribution by NEA
-
Supernus Announces Distribution of Common Stock by NEA
-
Delivery App Local Roots Expands its Fresh Food Marketplace to Include Neighbor Vendors
-
Form SC 13D/A ARDELYX, INC. Filed by: New Enterprise Associates 12, Limited Partnership
-
Philo – Next-Generation TV Platform – Announces $10M Financing
-
Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient Advocacy Position to Prepare for Further Clinical Development of VTS-270 in Niemann-Pick Disease Type C (NPC)
-
Placester Websites Now Has 95 Percent of Agent IDX Coverage in United States
-
ARCA biopharma Announces $37 Million Private Placement
-
Synlogic to Present at Several Upcoming Scientific and Industry Conferences
-
XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
-
Form SC 13D/A TESARO, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
-
Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
-
Lattice Engines Raises $28 Million
-
Fetchr Raises $11M To Revolutionize Shipping & Logistics And Bring New Opportunities to American Retailers
-
Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
-
Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
-
Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide (RM-493) in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
-
Blend Closes $6.3 Million in Series A to Expand Gen Z Social App
-
Ardelyx (ARDX) Announces $77.8M Common Stock, Warrants Offering
-
Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
-
Form 4 TESARO, Inc. For: Jun 01 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Placester Publisher Network Grows with Addition of Dallas Morning News and Denton Record-Chronicle
-
Transifex and e2f Deliver Integrated Services for Localization Automation
-
Transifex Announces Strategic New Partnerships With Translation Providers, Offering Flexible Options for Localization Automation
-
Lax Sports Network and ViewLift Present Live Streaming, Lacrosse-Focused Media Network

